We have located links that may give you full text access.
ENGLISH ABSTRACT
JOURNAL ARTICLE
REVIEW
[Treatment of bone metastasis by denosumab, the human monoclonal neutralizing antibody to RANKL].
Nihon Rinsho. Japanese Journal of Clinical Medicine 2012 December
Solid cancers such as breast, prostate and lung cancer have a predilection for spreading to bone. Accumulating data suggest that the crosstalk between metastatic cancer cells and bone-resorbing osteoclasts plays a central role in the development and progression of bone metastases. Recent studies have revealed that osteoblasts mediate this crosstalk by expressing the receptor activator of NF-kappaB ligand (RANKL) in response to cancer-produced osteotropic factors. The RANKL promotes osteoclast formation and bone resorption via the binding to RANK expressed in hematopoietic osteoclast precursor cells and mature osteoclasts. Denosumab is the humanized anti-RANKL neutralizing monoclonal antibody and thus would be a specific and effective therapeutic agent for the treatment of bone metastases. In fact, clinical studies clearly demonstrated that denosumab significantly inhibited the development of skeletal-related events associated with bone metastases and indicate its usefulness for bone metastases.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app